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Abstract In this paper we report the development of
highly sensitive, selective, and accurate stable isotope dilu-
tion gas chromatography negative chemical ionization mass
spectrometry (GC-NCI-MS) methods for quantification of
peroxisomal 
 
b
 
-oxidation intermediates of pristanic acid in
human plasma: 2,3-pristenic acid, 3-hydroxypristanic acid,
and 3-ketopristanic acid. The carboxylic groups of the inter-
mediates were converted into pentafluorobenzyl esters,
whereas hydroxyl groups were acetylated and ketogroups
were methoximized. Hereafter, the samples were subjected
to clean-up by high performance liquid chromatography.
Analyses were performed by selected monitoring of the car-
boxylate anions of the derivatives. Control values of all
three metabolites were established (2,3-pristenic acid: 2–48
 
n
 
m
 
, 3-hydroxypristanic acid: 0.02–0.81 n
 
m
 
, 3-ketopristanic
acid: 0.07–1.45 n
 
m
 
). A correlation between the concentra-
tions of pristanic acid and its intermediates in plasma was
found. The diagnostic value of the methods is illustrated by
measurements of the intermediates in plasma from patients
with peroxisomal disorders. It is shown that in generalized
peroxisomal disorders, the absolute concentrations of 2,3-
pristenic acid, 3-hydroxypristanic acid, and 3-ketopristanic
acid were comparable to those in the controls, whereas rela-
tive to the pristanic acid concentrations these intermediates
were significantly decreased. In bifunctional protein defi-
ciency, elevated levels of 2,3-pristenic acid and 3-hydroxy-
pristanic acid were found. 3-Ketopristanic acid, although
within the normal range, was relatively low when compared
to the high pristanic acid levels in these patients.
 
—Ver-
 
hoeven, N. M., D. S. M. Schor, E. A. Struys, E. E. W. Jan-
sen, H. J. ten Brink, R. J. A.
 
 
 
Wanders, and C. Jakobs.
 
 Analysis
of pristanic acid 
 
b
 
-oxidation intermediates in plasma from
healthy controls and patients affected with peroxisomal dis-
orders by stable isotope dilution gas chromatography mass
spectrometry. 
 
J. Lipid Res.
 
 1999. 
 
40:
 
 260–266.
 
Supplementary key words
 
2,3-pristenic acid 
 
•
 
 3-hydroxypristanic acid 
 
•
 
3-ketopristanic acid 
 
•
 
 Zellweger syndrome 
 
•
 
 bifunctional protein 
 
•
 
 diag-
nosis 
 
•
 
 stable isotopes
 
In higher eukaryotes, including humans, oxidation of
fatty acids takes place in both mitochondria and peroxi-
somes. Straight-chain fatty acids with short, medium, and
long chains are mainly degraded in mitochondria,
whereas very long chain fatty acids and branched-chain
fatty acids, like pristanic acid (2,6,10,14-tetramethylpenta-
decanoic acid) are oxidized in peroxisomes. In addition,
the side chains of the bile acid intermediates di- and trihy-
droxycoprostanic acid (DHCA and THCA) are 
 
b
 
-oxidized
within the peroxisome (see refs. 1 and 2 for reviews).
Mitochondrial and peroxisomal 
 
b
 
-oxidation proceed via
similar mechanisms, but the enzymes are different. In hu-
man peroxisomes, the first step of 
 
b
 
-oxidation, which in-
volves the FAD-dependent dehydrogenation of acyl-CoA
esters to their corresponding 
 
trans
 
-2-enoyl-CoA esters is
catalyzed by two distinct acyl-CoA oxidases (3–5). One of
these oxidases acts on saturated straight-chain acyl-CoA es-
ters with different chain lengths. The other oxidase,
branched-chain acyl-CoA oxidase, catalyses the dehydro-
genation of pristanoyl-CoA to 2,3-pristenoyl-CoA and of
di- and trihydroxycoprostanoyl-CoA to their unsaturated
analogues (5).
The second and third steps of peroxisomal 
 
b
 
-oxidation
are catalyzed by multifunctional proteins. Recent work has
shown that at least two multifunctional proteins are active
in peroxisomes, multifunctional protein 1 and 2 (MFP1
and MFP2) (6–10). These enzymes differ in substrate
specificity and in stereospecificity. The current concept is
that MFP1 acts on straight-chain saturated fatty acids and
is specific for the 
 
l
 
-configuration of the 3-hydroxyacyl-CoA
 
Abbreviations: GC-NCI-MS, gas chromatography-negative chemical
ionization mass spectrometry, PFB-Br, pentafluorobenzylbromide, HPLC,
high performance liquid chromatography.
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esters. MFP2, in contrast, forms and converts specifically
 
d
 
-3-hydroxyacyl-CoA esters and is involved in chain-short-
ening of the bile acid intermediates and of pristanic acid
(8–10). Thiolytic cleavage of 3-ketoacyl-CoA esters is also
catalyzed by two different enzymes within the peroxisome.
A clofibrate-inducible 3-ketoacyl-CoA thiolase acts on
straight-chain 3-ketoacyl-CoA esters (11), whereas branched-
chain 3-ketoacyl-CoA esters are thiolytically cleaved by 58
kDa sterol carrier protein X, a non-clofibrate-stimulated
enzyme (12).
It is generally assumed that the peroxisomal oxidation
of fatty acids only involves chain-shortening and does not
go to completion as the peroxisomal acyl-CoA oxidases do
not accept short chain acyl-CoAs as substrates (13, 14). Re-
cently, we demonstrated that pristanic acid undergoes
three cycles of 
 
b
 
-oxidation in peroxisomes, after which
further oxidation occurs inside mitochondria (15).
Pristanic acid originates partly from phytanic acid
(3,7,11,15-tetramethylhexadecanoic acid) and partly from
the diet. Different peroxisomal disorders in which pris-
tanic acid accumulates have been described (see ref. 16
for overview). This accumulation of pristanic acid is never
the sole biochemical abnormality in these disorders. In
generalized peroxisomal disorders, in which no function-
ally active peroxisomes are present, pristanic acid accumu-
lation is accompanied by accumulations of phytanic acid,
very long chain fatty acids, DHCA and THCA, and pipe-
colic acid and decreased concentrations of other metabo-
lites. In peroxisomal bifunctional protein deficiency and
peroxisomal 3-ketoacyl-CoA thiolase deficiency, very long
chain fatty acids, bile acid intermediates, and pristanic
acid accumulate (17–19).
Although the known mechanism of 
 
b
 
-oxidation of fatty
acids implies that pristanic acid is converted into 2,3-pris-
tenoyl-CoA, 3-hydroxypristanoyl-CoA, and 3-ketopristanoyl-
CoA (
 
Fig. 1
 
), the existence of these intermediates has not
been proven so far. Furthermore, it was not known whether
or not these intermediates were detectable in plasma. There-
fore, we developed sensitive methods to quantify these inter-
mediates in plasma from healthy controls. In order to investi-
gate the possible role of these methods in the differential
diagnosis of peroxisomal disorders, we measured pristanic
acid intermediates in plasma samples obtained from a large
number of patients affected with peroxisomal disorders in
which pristanic acid oxidation is disturbed.
MATERIALS AND METHODS
 
Biological samples
 
Human control plasma samples were obtained from subjects
without a metabolic disorder and without liver and kidney pa-
thology. Patient samples were obtained from patients suffering
from peroxisomal disorders. The diagnosis was made by analysis
of very long chain fatty acids, phytanic acid, pristanic acid, pipe-
colic acid, and bile acid intermediates in plasma. The diagnoses
were confirmed by enzyme analysis, immunoblotting, and some-
times by complementation studies.
 
Synthesis of standards
 
The synthesis of pristanic acid and [2-methyl-
 
2
 
H
 
3
 
]pristanic
acid has been described before (20). The key intermediate in the
synthesis of unlabeled and deuterated standards not previously
prepared was 4,8,12-trimethyltridecanal (
 
I
 
). It is readily accessi-
ble via oxidation of the corresponding alcohol 4,8,12-trimethyl-
tridecan-1-ol (20). Coupling of this aldehyde 
 
I
 
 with suitable re-
agents forms a useful approach to build up the structure of
pristanic acid derivatives at choice.
Fig. 1. Peroxisomal b-oxidation of pristanoyl-CoA. Branched-
chain acyl-CoA oxidase converts pristanoyl-CoA into 2,3-pristenoyl-
CoA. Bifunctional protein first forms 3-hydroxypristanoyl-CoA,
which is further metabolized to 3-ketopristanoyl-CoA. The 58 kDa
sterol carrier protein X thiolytically cleaves 3-ketopristanoyl-CoA,
yielding propionyl-CoA and 4,8,12-trimethyltridecanoyl-CoA. In
generalized peroxisomal disorders, all steps of peroxisomal b-oxi-
dation are impaired. In bifunctional protein deficiency, one of the
components or both components of the bifunctional enzyme are
deficient; BP, bifunctional protein.
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Reformatsky reaction of aldehyde 
 
I
 
 with ethyl 2-bromopropi-
onate provided ethyl 3-hydroxypristanate, which was converted
into free 3-hydroxypristanic acid and ethyl 3-ketopristanate. Con-
densation of aldehyde 
 
I
 
 with malonic acid via the Doebner modi-
fication of the Knoevenagel reaction was applied for the synthesis
of 2,3-pristenic acid.
 
4,8,12-Trimethyltridecanal (I)
 
Pyridinium chlorochromate (1 g) was added to a solution of
4,8,12-trimethyltridecan-1-ol (1 g) in methylene chloride (30
ml). After stirring for 2 h at room temperature the solvent was
evaporated, and the residue was extracted with petroleum ether
(bp 40
 
8
 
–65
 
8
 
C). The extract was filtered over celite to remove
some remaining solid, and concentrated to yield aldehyde 
 
I
 
 (0.88
g) as an almost colorless oil.
 
3-Hydroxypristanic acid ethyl ester (II)
 
A solution of 
 
d
 
,
 
l
 
-2-bromopropionic acid ethyl ester (2 g) in ben-
zene–ether 1:1 (5 ml) was slowly added to a suspension of Zn (1 g)
in benzene–ether 1:1 (30 ml), and heated to reflux. Aldehyde 
 
I
 
(0.88 g), dissolved in benzene–ether 1:1 (5 ml) was slowly added,
and the reaction mixture was refluxed for 6 h. After cooling, the
solution was filtered over celite, acidified with 2 N HCl, and ex-
tracted with petroleum ether (bp 40
 
8
 
–65
 
8
 
C) (2 
 
3
 
 25 ml). The
combined extracts were washed with brine, dried with MgSO
 
4
 
, fil-
tered, and concentrated. Column chromatography over silica (50
g) with 1% ethyl acetate–petroleum ether (bp 40
 
8
 
–65
 
8
 
C) gave 
 
II
 
(0.88 g) as an almost colorless oil (mixture of isomers).
 
3-Hydroxypristanic acid (III)
 
II
 
 (60 mg) was saponified by treating it with KOH (150 mg) in
ethanol (3 ml) at reflux temperature for 2 h. After cooling and
diluting with water (3 ml), the mixture was acidified and ex-
tracted with ethyl acetate (2 
 
3
 
 10 ml). The combined extracts
were dried with MgSO
 
4
 
, filtered, and concentrated to yield 3-hy-
droxypristanic acid (55 mg) as a slightly colored oil (mixture of
isomers). The chemical purity of the sample was determined by
comparing the flame ionization detector (FID) response of the
sample (relative to a reference compound) with the theoretical
FID response based on the effective carbon number. The purity
of 3-hydroxypristanic acid was thus estimated at 23%.
 
3-Ketopristanic acid ethyl ester (IV)
 
Pyridinium chlorochromate (0.3 g) was added to a solution of
 
II
 
 (0.2 g) in methylene chloride (20 ml), and the mixture was
stirred for 4 h at room temperature. The solvent was evaporated,
and the residue was extracted with petroleum ether (bp 40
 
8
 
–65
 
8
 
C)(2 
 
3
 
15 ml). The combined extracts were filtered over celite and con-
centrated to yield 
 
IV
 
 as a slightly colored oil (0.2 g) with a purity
of 69% as determined as described for 3-hydroxypristanic acid.
 
2,3-Pristenic acid (V)
 
Methylmalonic acid (0.2 g) was solved in pyridine (1 ml) and
cooled with ice. A solution of 
 
I
 
 (0.4 g) in pyridine (1 ml) was
slowly added, followed by 2 drops of piperidine. The solution was
warmed at 50
 
8
 
C for 36 h in the dark. After cooling, the mixture
was diluted with water (2 ml), acidified with HCl (2 N), and ex-
tracted with ethyl acetate (2 
 
3
 
 5 ml). The combined extracts
were washed with brine, dried with MgSO
 
4
 
, filtered, and concen-
trated. The crude product was purified by column chromatogra-
phy over silica with 1% ethyl acetate–petroleum ether (bp 40
 
8
 
–
65
 
8
 
C), giving 2,3-pristenic acid (0.2 g) as a colorless oil (mixture
of isomers) with a purity of 69% as determined by FID response.
 
2
 
H
 
3
 
-labeled standards
 
The [2-methyl-
 
2
 
H
 
3
 
]-labeled standards were synthesized from
aldehyde 
 
I
 
 in an analogous manner. The Reformatsky reaction
was conducted with 
 
d
 
,
 
l
 
-[3,3,3-
 
2
 
H
 
3
 
]2-bromopropionic acid ethyl
ester, prepared from [3,3,3-
 
2
 
H
 
3
 
]propionic acid by 
 
a
 
-bromination
using bromine and red phosphorus and quenching of the inter-
mediate acyl bromide with ethanol. The Doebner condensation
was performed with [
 
2
 
H
 
3
 
]methylmalonic acid, prepared from di-
ethyl malonate and [
 
2
 
H
 
3
 
]iodomethane followed by saponifica-
tion of the resulting ester.
 
Sample preparation
 
2,3-Pristenic acid.
 
An aliquot of 25–500 
 
m
 
l plasma was taken,
depending on the availability of sample and the expected con-
centration of 2,3-pristenic acid. After addition of 0.015 nmol [2-
methyl-
 
2
 
H
 
3
 
]pristenic acid as internal standard, 2 ml freshly pre-
pared 10% 6 
 
m
 
 HCl in acetonitrile was added, after which the
sample was hydrolyzed for 45 min at 100
 
8
 
C. Hereafter, 2 ml 1 
 
m
 
NaOH in methanol was added and the sample was saponified
again for 45 min at 100
 
8
 
C. These hydrolytic steps were per-
formed to ensure complete release of the fatty acid moiety from
CoA, from glycerol, from protein, etc. After acidification of the
sample with 350 
 
m
 
l 6 
 
m
 
 HCl it was extracted with 4 ml hexane.
The hexane was evaporated and the residue was derivatized with
100 
 
m
 
l pentafluorobenzylbromide (PFB-Br) (7% in acetonitrile)
and 10 
 
m
 
l triethylamine for 15 min at room temperature. After
derivatization, the sample was acidified by addition of 200 
 
m
 
l 0.5
 
m
 
 HCl and extracted with 1 ml hexane. After evaporation of the
hexane, the residue was dissolved in 45 
 
m
 
l acetonitrile and puri-
fied by high performance liquid chromatography (HPLC) as de-
scribed below.
 
3-Hydroxypristanic acid.
 
For analysis of 3-hydroxypristanic acid
in plasma, an aliquot of 25–500 
 
m
 
l plasma was taken. [2-Methyl-
 
2
 
H
 
3
 
]3-hydroxypristanic acid (0.001 nmol) was added as internal
standard. The sample was hydrolyzed and derivatized with PFB-
Br as described for 2,3-pristenic acid. Hereafter, the sample was
derivatized with 100 
 
m
 
l acetic anhydride and 100 
 
m
 
l pyridine for
1 h at 80
 
8
 
C. After evaporation of the reagents, the residue was dis-
solved in 45 
 
m
 
l acetonitrile and purified by HPLC as described
below.
 
3-Ketopristanic acid.
 
For analysis of 3-ketopristanic acid in plasma,
to 100–500-
 
m
 
l aliquots of plasma, 0.55 pmol of [2-methyl-
 
2
 
H
 
3
 
]3-
ketopristanic acid ethyl ester was added as internal standard.
Methoxylamine
 
?
 
HCl (1 g/ml water) (200 
 
m
 
l) and a droplet of 6
 
m
 
 HCl were added, after which the sample was heated for 2 h at
80
 
8
 
C. After cooling, 500 
 
m
 
l 1 
 
m
 
 NaOH in methanol was added
and the samples were left overnight at room temperature to en-
sure hydrolysis under mild conditions. After acidification of the
samples with 100 ml 6 m HCl, they were extracted with 2 ml hex-
ane. The hexane fractions were evaporated under a nitrogen
stream. PFB-Br (100 ml) (7% in acetonitrile) and 10 ml triethyl-
amine were added, after which the samples were left at room
temperature for 15 min. After acidification of the samples with
200 ml 0.5 m HCl, extraction with 1 ml hexane, and evaporation of
the hexane, the residue was dissolved in 45 ml acetonitrile. Hereaf-
ter, the samples were purified by HPLC as described below.
Sample purification by reversed phase high performance 
liquid chromatography
A 20-ml aliquot of the prepared sample was applied onto a pre-
column (LC18DB, length: 1 cm, internal diameter 4.6 mm, parti-
cle size 5 mm, Supelco, Bellefonte, PA) coupled to a C18 analyti-
cal RP-HPLC column (LC18S, length 25 cm, internal diameter
4.6 mm, particle size 5 mm, Supelco, Belafonte) using 100% ace-
tonitrile as mobile phase with a flow rate of 1 ml/min. For 3-hy-
droxypristanic acid and 3-ketopristanic acid, a second analytical
C18 column (LC18S, length 15 cm, internal diameter 4.6 mm,
particle size 5 mm, Supelco) was coupled to the first analytical
column. Chromatography was performed at 458C (2,3-pristenic
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acid), 358C (3-hydroxypristanic acid), or 208C (3-ketopristanic
acid). Detection was accomplished with a UV detector at a wave-
length of 225 nm. Derivatized standards (10 mm) were used to de-
termine retention times of the analytes. Due to the constant perfor-
mance of the HPLC set up, we were able to use a time-programmed
fraction collector to collect 1-ml fractions, in spite of the fact that
the metabolites in the plasma samples were usually not detect-
able by the UV detector due to their low concentrations.
Gas chromatography mass spectrometry
2,3-Pristenic acid. GC separation of the PFB ester of 2,3-pris-
tenic acid was achieved on a very polar column (BPX70, 25 m 3
0.32 mm, film thickness 0.25 mm, Scientific Glass Engineering,
Ringwood, Australia) using helium as carrier gas. The injector
temperature was 2608C, the injection volume was 1 ml. After 1
min at 808C, the column temperature was raised with 58 per min
to 2508C. The interface temperature was set at 2808C, the source
temperature was 2508C. The mass spectrometer was used in the
negative chemical ionization mode. NH3 was used as ionization
gas at an optimized ion source pressure. Selected ion monitoring
(SIM) of the ions 2m/z 295 and 2m/z 298 was performed for 2,3-
pristenic acid and its labeled internal standard, respectively. The
two peaks that were observed in the SIM chromatogram were ana-
lyzed by high energy collision and constant B/E ratio linked scan-
ning. This way, the daughter spectrum of the carboxylate anion
of the fatty acid is produced, enabling confirmation of the posi-
tions of the methyl groups and the double bond in the molecule
(Kratos Concept 1 H mass spectrometer).
3-Hydroxypristanic acid and 3-ketopristanic acid. For GC separa-
tion of the PFB-acetyl derivative of 3-hydroxypristanic acid and
the PFB-methoxime derivative of 3-ketopristanic acid, a CPsil 19
CB capillary column (25m 3 0.25 mm, film thickness: 0.2 mm
Chrompack, Middelburg, The Netherlands) was used. The car-
rier gas was helium. The injector temperature was 3008C. One to
2 ml of sample was injected splitless. For 3-hydroxypristanic acid,
the initial GC temperature of 1608C was kept for 1 min, after
which the temperature was raised by 308C per min to 3208C. For
3-ketopristanic acid, the GC was held for 1 min at 1208C, after
which the temperature was increased by 358C per min to 3208C.
Hereafter, the GC was kept at 3208C for 5 min.
For both analyses, the interface temperature was 3008C, the
source temperature was 2508C. The mass spectrometer was used in
the negative chemical ionization mode with NH3 as ionization gas.
The ion source pressure was 9.1025 Torr. For 3-hydroxypristanic
acid and its labeled internal standard, the ions 2m/z 355 and 2m/z
358 were monitored. For 3-ketopristanic acid and its labeled inter-
nal standard, the ions 2m/z 340 and 2m/z 343 were monitored.
All GC-MS analyses were performed on a Hewlett-Packard sys-
tem (Hewlett-Packard 5890 series II and Hewlett-Packard Engine
5989B). Interassay reproducibility was assessed by quantifying the
analytes in two pooled plasma samples extracted and analyzed on
different days. Concentrations were determined based on cali-
bration curves processed on the same day.
RESULTS
The reproducibility of the quantifications of 2,3-pris-
tenic acid, 3-hydroxypristanic acid and 3-ketopristanic acid
are summarized in Table 1.
2,3-Pristenic acid
Chemical ionization mass spectrometry of 2,3-pristenic
acid PFB ester generates a mass spectrum showing a
prominent ion (2m/z 295) corresponding to (M-PFB)
(spectrum not shown). This ion was chosen for selected
ion monitoring (SIM) measurement. Figure 2 represents
the GC-NCI-MS chromatogram, recorded in the SIM
mode, from 2,3-pristenic acid in control human plasma
with added labeled internal standard. The internal stan-
dard shows two peaks with baseline separation. High en-
ergy collision and constant B/E ratio linked scanning
showed that both peaks consist of 2,3-pristenic acid only.
The second peak was the most prominent one, account-
ing for over 90% of the total amount of the compound. In
the plasma samples, both peaks were present. In all
plasma samples, the first peak accounted for ca. 3.5% of
the total amount of 2,3-pristenic acid. Quantification was
achieved by summation of both peaks. Control values of
2,3-pristenic acid were determined in 17 plasma samples
with normal pristanic acid concentrations (Table 2). The
ratios between 2,3-pristenic acid and pristanic acid in the
samples are summarized in Table 3. In Fig. 3, the correla-
tion between the pristanic acid and 2,3-pristenic acid con-
centrations in the samples is shown. Concentrations of
2,3-pristenic acid in plasma obtained from patients af-
fected with generalized peroxisomal disorders and iso-
lated bifunctional protein deficiency were measured
(Table 2). In Fig. 3 it is shown that the correlation be-
tween pristanic acid and 2,3-pristenic acid in patients is
different from those in controls.
3-Hydroxypristanic acid
The mass spectrum of the PFB-acetyl derivative of 3-
hydroxypristanic acid showed a prominent ion correspond-
ing to 2m/z 355 due to loss of PFB by chemical ionization.
SIM measurements were performed by monitoring this ion.
The results obtained with a control human plasma sample
are shown in Fig. 2. Both the acetyl derivative of the biolog-
ical 3-hydroxypristanate from the plasma and the chemi-
cally synthesized labeled internal standard show two peaks
with baseline separation. This phenomenon may be caused
by different gas chromatographic retention of different
stereoisomers of the compound. As the exact nature of the
two peaks was not known, quantification was achieved by
summation of both peaks. Table 2 shows the concentrations
of 3-hydroxypristanic acid in plasma from controls and pa-
tients affected with generalized peroxisomal disorders or
bifunctional protein deficiency. Table 3 summarizes the ra-
tios between the concentrations of 3-hydroxypristanic acid
and pristanic acid in the samples. In Fig. 3, the correlations
between the concentrations of 3-hydroxypristanic acid and
TABLE 1. Reproducibility of the determination of 2,3-pristenic 
acid, 3-hydroxypristanic acid and 3-ketopristanic acid
in 2 pooled plasma samples
Pool 1 Pool 2
nmol/l
2,3-Pristenic acid 10 6 1 (n 5 14) 6 6 1 (n 5 10)
3-Hydroxypristanic acid 0.18 6 0.09 (n 5 8) 0.14 6 0.12 (n 5 8)
3-Ketopristanic acid 0.28 6 0.04 (n 5 12) 0.20 6 0.04 (n 5 7)
Measurements were performed on different days by GC-NCI-MS.
Concentrations were calculated based on calibration curves processed
on the same day. Values are given as mean 6 SD.
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pristanic acid in the control samples are shown. In addi-
tion, the values from a patient affected with a generalized
peroxisomal disorder are included in the graph, to illus-
trate the difference from the controls.
3-Ketopristanic acid
Loss of PFB from 3-ketopristanate-PFB-methoxime dur-
ing chemical ionization resulted in the formation of one
prominent peak with 2m/z 340 in the mass spectrum of
this compound. This ion was chosen for SIM measurements.
The SIM chromatogram of the 3-ketopristanic acid deriva-
tive showed two peaks due to formation of two isomers
during methoxime derivatization. As expected, these two
peaks were always present in a fixed ratio, both in standard
samples and in plasma samples. Figure 2 depicts the SIM
chromatogram of a control plasma sample. Quantification of
3-ketopristanic acid in plasma was achieved by the use of cali-
bration curves from the synthesized 3-ketopristanic acid
ethyl ester. The concentrations of 3-ketopristanic acid in
plasma from controls and patients affected with peroxisomal
disorders are summarized in Table 2. In Table 3, the ratios
between 3-ketopristanic acid and pristanic acid, both in con-
trols and patients, are summarized. Figure 3 shows the corre-
lation between the concentrations of 3-ketopristanic acid
and pristanic acid in control samples. The patient with a gen-
eralized peroxisomal disorder is clearly abnormal.
DISCUSSION
In order to quantitate the low amounts of pristanic acid
and its oxidative metabolites 2,3-pristenic acid, 3-hydroxy-
pristanic acid, and 3-ketopristanic acid in plasma samples,
Fig. 2. GC-MS analysis of A: 2,3-pristenic acid in control human
plasma, monitoring 2m/z 295 and 2m/z 298 for 2,3-pristenate in
plasma and the internal standard respectively, B: 3-hydroxypristanic
acid in control human plasma, monitoring 2m/z 355 and 2m/z 358
for 3-acetoxypristanate in pooled human plasma and the internal
standard, respectively, and C: 3-ketopristanic acid in control human
plasma, monitoring 2m/z 340 and 2m/z 343 for 3-ketopristanate-
methoxime in plasma and the internal standard, respectively.
TABLE 2. Concentrations of 2,3-pristenic acid,
3-hydroxypristanic acid, and 3-ketopristanic acid in 
plasma from controls and patients with generalized
peroxisomal disorders or bifunctional protein deficiency
Subjects
Pristanic 
Acid
2,3-Pristenic 
Acid
3-OH-
Pristanic Acid
3-Ketopristanic
Acid
mM nM nM nM
Controls (n 5 17) 0.20–4.4 2–48 0.02–0.81 0.07–1.45
Generalized peroxisomal disorders
1 5.5 7 0.18 0.14
2 6.7 8 nd 0.07
3 7.1 6 0.28 0.35
4 9.7 26 0.32 0.14
5 16 5 nd nd
6 17 21 0.21 0.28
7 24 26 0.53 0.41
8 32 57 1.22 1.31
9 43 35 0.83 0.28
10 47 46 0.78 0.97
Isolated peroxisomal b-oxidation defects
1 0.22 13 nd nd
2 0.95 43 nd nd
3 4.9 262 nd nd
4 5.4 952 3.91 0.07
5 7.4 221 2.07 n.d.
6 33 2898 11.0 1.31
7 37 1449 6.2 nd
8 68 4354 15.2 2.28
9 282 12972 76 nd
Not determined, nd.
TABLE 3. Relative amounts of pristanic 
acid intermediates in plasma
Subjects
2,3-Pristenic/
Pristanic 3 103
3-OH-Pristanic/
Pristanic 3 103
3-Ketopristanic/
Pristanic 3 103
Controls 6–18 0.07–0.60 0.08–1.7
GPD 0.31–2.68 0.01–0.04 0.01–0.05
BPD 30–176 0.17–0.72 0.01–0.04
GPD, generalized peroxisomal disorders; BPD, bifunctional pro-
tein deficiency.
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a highly selective and sensitive technique is required.
Therefore, quantification was performed by stable isotope
dilution GC-NCI-MS. The concentrations of 2,3-pristenic
acid, 3-hydroxypristanic acid, and 3-ketopristanic acid in
control plasma samples were in the nanomolar range.
Early attempts to measure these low concentrations failed,
as coeluting compounds interfered in the SIM chromato-
grams. Therefore, extensive clean-up of the samples by
HPLC was introduced.
In controls, a clear correlation between the con-
centrations of pristanic acid and its intermediates was
demonstrated.
In generalized peroxisomal disorders, both phytanic
acid a-oxidation and pristanic acid b-oxidation are defi-
cient. The concentrations of phytanic and pristanic acids,
however, are not always elevated in plasma from affected
patients. In very young patients, intake of phytanic acid
and pristanic acid from the diet has been limited, which
explains the lack of accumulation in these patients (19).
We now demonstrate that in generalized peroxisomal dis-
orders, 2,3-pristenic acid is, in all cases except one, within
the control range. However, when comparing the concen-
trations of 2,3-pristenic acid with those of pristanic acid, it
is clear that 2,3–pristenic acid in plasma from these pa-
tients is relatively low. In addition, 3-hydroxypristanic acid
and 3-ketopristanic acid, although both within the control
ranges or even slightly elevated, were low relative to the
pristanic acid concentrations in these patients, as clearly
reflected in the respective ratios.
The observation that pristanic acid intermediates are
present in plasma from patients affected with generalized
peroxisomal disorders may point to some residual activity
of peroxisomal b-oxidation in these patients. However, it is
also possible that small amounts of these intermediates are
ingested with the diet and, due to defective b-oxidation, are
not degraded.
In bifunctional protein deficiency, accumulation of
pristanic acid occurs (18, 19). The accumulating pristanic
acid is thought to inhibit phytanic acid a-oxidation, result-
ing in elevated phytanic acid concentrations. As pristanic
acid accumulation is more pronounced than phytanic acid
accumulation in these patients, the ratio pristanic acid/
phytanic acid in plasma is increased (18). The present
work shows that 7 out of 9 patients affected with bifunc-
tional protein deficiency included in this study exhibited
elevated levels of 2,3-pristenic acid. In addition, in all sam-
ples from bifunctional protein-deficient patients analyzed,
3-hydroxypristanic acid was elevated. In all 9 patients, 2,3-
pristenic acid was elevated relative to the pristanic acid
concentration, whereas the 3-hydroxypristanic acid/pris-
tanic acid ratio was comparable to those in the controls.
This suggests that, due to a presumed deficiency of the 3-
hydroxyacyl-CoA dehydrogenase component of the bi-
functional protein, 3-hydroxypristanic acid accumulated.
This may then cause inhibition of the 2-enoyl-CoA hy-
dratase component, resulting in 2,3-pristenic acid accu-
mulation and, due to inhibition of branched-chain acyl-
CoA oxidase, accumulation of pristanic acid. This suggests
a phenomenon of feedback inhibition of enzymes by ac-
cumulating products.
In bifunctional protein deficiency, 3-ketopristanic acid
is expected to be low, regardless of whether the hydratase
or the dehydrogenase component of the bifunctional en-
zyme is deficient. Indeed, the 3-ketopristanic acid concen-
trations relative to the concentration of pristanic acid
were decreased in bifunctional protein deficiency.
Measurement of pristanic acid and 2,3-pristenic acid in
plasma provides a fast method to distinguish between gen-
Fig. 3. Correlation between the concentrations of pristanic acid
and its b-oxidation intermediates 2,3-pristenic acid, 3-hydroxypris-
tanic acid, and 3-ketopristanic acid in control human plasma. The
patients affected with a generalized peroxisomal disorder or bi-
functional protein deficiency are clearly distinct; R, coefficient of
correlation.
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eralized peroxisomal disorders and bifunctional protein
deficiency, necessitating only one plasma sample. Al-
though the ratio of pristanic acid/phytanic acid, being
normal in generalized peroxisomal disorders and elevated
in bifunctional protein deficiency, already hints at a diag-
nosis, this parameter is not always reliable. In our experi-
ence, the pristanic acid/phytanic acid ratio is sometimes
elevated in patients suffering from atypical generalized
peroxisomal disorders. Measurement of 2,3-pristenic acid
in samples from these patients will give additional infor-
mation for the correct diagnosis.
In addition, in isolated peroxisomal b-oxidation de-
fects, the levels of pristanic acid intermediates may help to
determine the exact defect. In bifunctional protein defi-
ciency, elevated levels of 2,3-pristenic acid are always ex-
pected. 3-Hydroxypristanic acid is also expected to be ele-
vated (in case of a 3-hydroxyacyl-CoA dehydrogenase
deficiency) or low (in case of a hydratase deficiency).
When 3-ketoacyl-CoA thiolase is deficient, accumulation
of 3-ketopristanic acid is expected. This latter hypothesis
could, unfortunately, not be verified as no plasma sample
of the only known patient affected with peroxisomal 3-
ketoacyl-CoA thiolase deficiency was available (19, 21).
In summary, we have demonstrated, for the first time,
the existence of 2,3-pristenic acid, 3-hydroxypristanic
acid, and 3-ketopristanic acid in human plasma. Further-
more, we have shown that in generalized peroxisomal
disorders relatively low concentrations of these interme-
diates are found, whereas in the cases of bifunctional
protein deficiency, accumulation of 2,3-pristenic acid
and 3-hydroxypristanic acid occurs. The method enables
distinction between generalized peroxisomal disorders
and isolated peroxisomal b-oxidation defects. Future
studies will focus on the investigation of plasma samples
from patients with unknown peroxisomal fatty acid oxi-
dation defects.
Manuscript received 3 February 1998 and in revised form 25 June 1998, and
in re-revised form 14 October 1998.
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